Hepatocellular Carcinoma Growth and Molecular Aggressiveness (UniRer)
|Cirrhosis Hepatocellular Carcinoma|
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||"Integrated Molecular/Imaging Technology for Characterization of Biological Aggressiveness of HCC in Patients Candidate to Liver Transplant"|
- Survival [ Time Frame: 2 years ]Survival will be compared between patients with rapidly and slowly growing HCCs
- Response to therapy [ Time Frame: 2 years ]Response to therapy (liver transplant, resection, TACE) will be compared between rapidly and slowly growing HCCs
Biospecimen Retention: Samples With DNA
|Study Start Date:||June 2008|
|Study Completion Date:||August 2012|
|Primary Completion Date:||May 2012 (Final data collection date for primary outcome measure)|
Organ allocation in our region is regulated according to MELD score. Patients with hepatocellular carcinoma (HCC) receive an additional score depending on size of the tumor and the time spent in transplant waiting list. However, the advantage given to these patients is uniform and does not take into account the profound biological heterogeneity of individual HCCs. To make the additional score righteous, the investigators need to identify patients with aggressively growing HCC who require salvage transplantation while those with slow-growing HCC do not deserve the additional score.
All cirrhotics with suspect HCC identified at routine US screening will be therefore enrolled in the prospective imaging and bio-molecular study.
They will be subjected to two computed tomography (CT) exams at 7 weeks interval to define fractional tumor growth and imaging traits, baseline US-guided liver biopsy for microarray and histochemical characterization, serum sampling for cytokine assay. Survival, disease-free survival after downstaging and transplant outcome will be recorded and analyzed in relation with imaging and molecular data. The investigators expect to set up an accurate imaging and molecular diagnostic tool able to identify patients with aggressive HCC requiring urgent access to transplant, reliable in predicting survival, standardisable and not too expensive.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01657695
|Modena, Italy, 41124|
|Principal Investigator:||Erica Villa, MD||University of Modena and Reggio Emilia|